TACC3 and lung adenocarcinoma: A total of 77.8% (14 of 18), 92.3% (12 of 13), and 13.3% (2 of 15) of patients had lung adenocarcinoma; one patient (5.6%) harbouring the FGFR-TACC3 fusion in the oncogene-positive IO group was defined as having not otherwise specified NSCLC (NOS-NSCLC); and the other patient had squamous cell carcinoma.